stars 1 stars 2 stars 3

Inhalation Sciences is a Swedish, cutting-edge CRO specializing in inhaled drug development for NCE's, generics, and biologics. Our services enable data-driven decision-making early in development, helping minimize risk, reduce timelines, and lower costs. Unique deliverables enabled by our proprietary PreciseInhale® technology platform; • Precision dosing of aerosol • Unmatched precision in pharmacokinetic data - correlating to in-human results • Unprecedented clinical predictability • Significantly de-risking inhaled drug development • Reduced use of API and animals Our multidisciplinary team brings extensive contract research experience in inhalation drug development. Our founder and CSO, Per Gerde is a recognized world authority and Associate Professor of Inhalation Toxicology at the Institute of Environmental Medicine, Karolinska Institute in Sweden. Visit our website: http://www.inhalation.se/ Visit our labs: Kliniskt Forskningscentrum KFC Novum plan 6 hiss A Hälsovägen 7 141 57 Huddinge, Sweden Visitor entrance, Blickagången 6, elevator E, level 6

Inhalation Sciences Sweden AB Questions

The Inhalation Sciences Sweden AB annual revenue was $1 million in 2026.

Pontus Nobreus is the CEO of Inhalation Sciences Sweden AB.

9 people are employed at Inhalation Sciences Sweden AB.

The NAICS codes for Inhalation Sciences Sweden AB are [54171, 333, 541713, 5417, 54, 541, 33].

The SIC codes for Inhalation Sciences Sweden AB are [873, 87, 358, 35].

G2 Leader Summer 2026 G2 Best Est ROI Mid-Market Summer 2026 G2 Easiest Admin Mid-Market Summer 2026 G2 Most Implementable Summer 2026 G2 Best Results Mid-Market Summer 2026 G2 Lead Capture Mid-Market Summer 2026 Inc Fastest Growing Private Companies 2026 Inc Best Workplace 2026
g2crowd
G2Crowd Trusted
chromestore
300K+ Plugin Users